CNS Pharmaceuticals’ (NASDAQ: CNSP) novel anthracycline Berubicin, which has been developed to treat diseases with unmet need such as the deadly glioblastoma (“GBM”), appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier in targeting tumors of the central nervous system. “Berubicin was the drug candidate subject of a small-scale phase 1 clinical trial in 2006 that evaluated its safety, which was notable because one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent 16 years. Nearly half of the trial’s patients experienced a statistically significant improvement in clinical benefit. GBM patients, in general, have a median survival rate of only 14.6 months after diagnosis, which is evidence of the need for an effective treatment for the thus-far incurable cancer,” a recent article reads. “Anthracyclines like Berubicin are among the most powerful chemotherapy drugs and are effective against more types of cancer than any other class of chemotherapeutic agents, according to the company. They are designed to utilize natural processes to cause deoxyribonucleic acid (‘DNA’) damage in targeted cancer cells by interfering with the action of cell-growth enzyme topoisomerase II.”
To view the full article, visit https://ibn.fm/L8O6l
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.